Overall Survival and Local Recurrence (%) After Curative Surgery With or Without Radiotherapy With or Without Chemotherapy
| Series | No. of patients | Radiation dosage, Gy/fractions/d | Concurrent chemotherapy (5FU) + radiotherapy | Maintenance chemotherapy | Frequency of local recurrence | 5-year survival | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S | S + R | S + C | S + R + C | S | S + R | S + C | S + R + C | |||||
| Preoperative | ||||||||||||
| Boulis-Wassif and associates, (19) 1984 (EORTC) | 247 | 34.5/15/19 | Yes | None | — | 15 | — | 15 | — | 59 | — | 46 |
| Postoperative | ||||||||||||
| Tveit and associates, (20) 1995 (Norway) | 144 | 46/23/30 | Yes | None | 30* | — | — | 12* | 49* | — | — | 64* |
| Gastrointestinal Tumor Study Group, (10), (11) 1985, 1986 | 202 | 40–48/20–26/30–39 | Yes | 5FU/MeNU | 24 | 20 | 27 | 11 | 46† | 52 | 56 | 58† |
| Mansour and associates, (21) 1991 (ECOG) | 237 | 45–50.4/25–28/35–38 | No | 5FU/MeNU | — | NA | NA | NA | — | 46 | 47 | 50 |
| Krook and associates, (22) 1991 (NCCTG) | 204 | 50.4/28/38 | Yes | 5FU/MeNU | — | 25* | — | 14* | — | 47† | — | 58† |
S = surgery, S + R = surgery and radiotherapy, S + R + C = surgery, radiotherapy and chemotherapy, NA = not available, 5FU = 5-fluorouracil, MeNU = methylcyclohexylchlorethylnitrosourea, ECOG = Eastern Cooperative Oncology Group, NCCTG = North Central Cancer Trials Group
↵* p ≤ 0.05
↵† p ≤ 0.05 after 7 years’ follow-up